Therefore, after long-term treatment with sorafenib, liver cancer cells with low YAP1 expression are eliminated, leaving cells with high YAP1 expression, resulting in increased YAP1 expression in sorafenib-resistant HCC cells. Here, YAP1 is linked to liver cancer.